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1. Introduction 
Substantial research and clinical effort has been directed toward the understanding, 
identification and management of coronary artery disease (CAD). As a result, the processes 
of cholesterol accumulation and inflammation that lead to large vessel occlusions have been 
fully elucidated. In contrast to those with CAD, many patients have symptoms of angina 
and reductions in coronary flow reserve despite normal coronary angiography of the large 
epicardial arteries. In this situation the vessels that limit flow to myocardium are the more 
distal epicardial prearterioles and intramyocardial arterioles – vessels typically too small to 
be directly visualized by conventional coronary angiography. These vessels comprise the 
coronary microcirculation. Coronary microvascular dysfunction (CMVD), in contrast to 
CAD, continues to be poorly understood and difficult to manage. In addition, the presence 
of CMVD can be a confounding factor in the management of patients with CAD. 
2. Anatomy and physiology of the coronary microcirculation 
The coronary arterial network is generally divided into three sequential morphological 
zones. The large epicardial coronary arteries decrease in diameter from 2-5 to 500 microns as 
they branch off of the aorta and travel distally along the epicardium. Distal to the large 
coronary arteries are epicardial pre-arterioles that decrease in diameter from 500 to 100 
microns. Finally, the pre-arterioles give rise to intramyocardial arterioles that measure 100 
microns or less in diameter. Coronary arterioles and pre-arterioles dilate and constrict in 
large part through feedback mechanisms in order to maintain a constant blood flow shear 
stress across the interior surface of the vessels (Camici & Crea, 2007). 
Blood flow shear stress is the average laminar force per unit of cross sectional area of the 
vessel surface, applied parallel to the vessel wall. The interior surfaces of all blood vessels 
are lined with endothelial cells. Endothelial cells detect changes in blood flow shear stress 
and respond with signals to the surrounding smooth muscle cells to either relax in response 
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to an increase in shear stress or contract in response to a decrease in shear stress. It remains 
unclear exactly how endothelial cells are able to detect and respond to these fluctuations in 
shear stress. Some studies have identified the protein caveolin-1 (CAV-1, which forms 
caveolae) as a receptor in this process (Traub & Berk, 1998). Other evidence suggests that 
endothelial cells respond to an increase in shear stress by activating endothelial nitric oxide 
synthase (eNOS) which in turn catalyzes the production and release of nitric oxide (NO), a 
potent vasodilator (Traub & Berk, 1998). The roles of CAV-1 and of eNOS are examples of 
many different pathways involved in the process of arteriolar dilatation. Arterioles (500 
microns or less) located deep within the myocardium are exposed to a complex milieu of 
hormones and cytokines, some of which also perform roles essential to the fine auto-
regulation of vasoconstriction and vasodilatation.  
Normal function of the microcirculation is dependent on the production and bioavailability 
of nitric oxide (NO) (Traub & Berk, 1998). NO is produced in the endothelium by nitric 
oxide synthase (NOS). There are three isoforms of NOS; endothelial NOS (eNOS), inducible 
NOS (iNOS) and neuronal NOS (nNOS). NOS converts L-arginine into nitric oxide (NO), 
which diffuses into surrounding vascular smooth muscle cells (VSMC) and induces 
relaxation. Relaxation of VSMC is caused by the binding of NO to guanylyl cyclase and 
subsequent activation of the enzyme. Guanylyl cyclase catalyzes the dephosphorylation of 
GTP to produce cGMP, which is a second messenger for many cellular functions. Cyclic 
GMP induces smooth muscle relaxation by suppressing intracellular entry of calcium 
through voltage-gated calcium channels, by activating (via phosphorylation) ATP-
dependent potassium channels, or by activating the enzyme myosin light chain 
phosphatase, which dephosphorylates myosin light chains and relaxes smooth muscle 
(Traub & Berk, 1998). Subsequently, vasodilation occurs and blood flow is increased. The 
bioavailability of NO is critical to normal vascular function. 
3. Clinical presentation of coronary microvascular dysfunction 
In addition to occlusion of a coronary artery, myocardial ischemia may be caused by 
resistance to coronary blood flow related to increased vascular tone. In the healthy 
individual, epicardial coronary arteries contribute minimal resistance to blood flow as long 
as they are free of occlusive disease (Maseri, Beltrame, & Shimokawa, 2009). The pre-
arterioles contribute about 20% of the total resistance to blood flow (Maseri et al., 2009), and 
the remainder of the coronary microcirculation collectively accounts for 60%-80% of the total 
resistance to blood flow (John F. Beltrame, Crea, & Camici, 2009). Dysfunction of a single 
arteriole would not affect overall cardiac function. However, an abnormal increase in 
resistance to blood flow through an entire network of coronary arterioles could cause 
ischemia in a large segment of myocardium. In some cases, coronary microvascular 
dysfunction can cause ischemia to a similar degree as that caused by large epicardial 
coronary artery occlusions. Indeed, up to 30% of patients who present with angina and 
myocardial infarction have patent epicardial coronary arteries at the time of cardiac 
catheterization (Romeo, Rosano, Martuscelli, Lombardo, & Valente, 1993; Vesely & 
Dilsizian). In some cases, cardiac angiography is able to detect a “slow blood flow 
phenomenon” based on delayed opacification of the microcirculation (J. F. Beltrame, 
Limaye, & Horowitz, 2002; Tambe, Zimmerma.Ha, Demany, & Mascaren.E, 1972), but in 
general the use of cardiac angiography is limited to the observation of only those vessels 
that are 500 microns or larger in size (Vesely & Dilsizian). Most studies suggest that 
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coronary microvascular dysfunction (CMVD) remains stable over time and is associated 
with a good overall prognosis in the majority of cases. Nonetheless, as many as 20-30% of 
patients with CMVD develop progressive symptoms of angina, sustain acute myocardial 
infarctions, and demonstrate reductions in cardiac function (G. A. Lanza & Crea, 2010). 
Some markers of ischemia in such patients include increased levels of plasma lactate and 
lipid peroxidase (both byproducts of anaerobic glucose metabolism), decreased oxygen 
saturation within the coronary sinus, and a shift in myocardial phosphate utilization on 
magnetic resonance spectroscopy (G. A. Lanza & Crea, 2010).  
 
Fig. 1. Nitric oxide (NO) is produced in endothelial cells using L-arginine as a substrate. NO 
diffuses readily across plasma membranes to vascular smooth muscle cells. The synthesis of 
cyclic guanylyl monophosphate (cGMP) from guanylyl triphosphate (GTP) causes 
relaxation of vascular smooth muscle, and subsequent vasodilation. 
4. Classification of coronary microvascular dysfunction 
There are several broad categories of CMVD (Camici & Crea, 2007). The first category is 
classified as CMVD in the absence of obstructive large vessel CAD, based on the 
macroscopic findings at the time of coronary catheterization. The second category of 
microvascular dysfunction is defined as CMVD in the presence of cardiomyopathy. The 
third category is classified as CMVD in the presence of obstructive large vessel CAD. 
Clearly, in this subtype, the cardiac risk factors that induce the formation of occlusive 
disease within the large epicardial coronary arteries may also negatively impact blood flow 
through the small coronary arterioles.  
The fourth category is classified as iatrogenic coronary microvascular dysfunction. This type 
of CMVD refers to the paradoxical “no re-flow phenomenon” associated with reperfusion 
injury. This occurs in the microcirculation, downstream of arteries recently made patent by 
thrombolysis, percutaneous angioplasty, stenting, or bypass grafting. This “no re-flow 
phenomenon” is identified based on persistent low blood flow (according to the TIMI flow 
scale (Antman et al., 1999)) after successful revascularization procedures. TIMI is an 
acronym for “thrombolysis in myocardial infarction” (Antman et al., 1999), and the flow 
scale measures the amount of time it takes (in seconds) for contrast dye to fill the length of a 
coronary artery during angiography (Camici & Crea, 2007).  
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One mechanism of reperfusion injury is distal embolization of plaque and thrombin in the 
small arterioles. Increased adrenergic tone following an acute cardiac event could cause 
vasoconstriction in the coronary microcirculation. However, in some cases, microvascular 
blood flow deficits have been measured in small vessels remote from the region of the 
infarct and revascularization (Gregorini et al., 1999), which are not explained by “no-reflow” 
or adrenergic stimulation. Moreover, microvascular reperfusion abnormalities can persist 
for as long as 3-6 months following the revascularization (John F. Beltrame et al., 2009). 
Myocardial ischemia initially causes a decrease in the level of intracellular ATP, a change 
from aerobic to anaerobic metabolism, a buildup of toxic byproducts of anaerobic metabolism, 
and a decrease in the pH. The restoration of oxygenated blood flow to recently ischemic tissue 
induces a cascade of toxic events. Some of these events might include, but are not limited to, 
abnormal leukocyte or platelet aggregation, complement activation, osmotic overloading of 
the mitochondria, and subsequent dysfunction of the microcirculation. 
5. Cardiac Syndrome X 
“Syndrome X” is the label used to describe an additional clinical phenomenon associated 
with CMVD. The label “syndrome X” typically refers to the presence of all of the following 
characteristics: angina or angina-like chest pain with exertion; ST- segment abnormalities 
during cardiac stress testing; absence of cardiac wall motion abnormalities during stress 
testing; and normal and patent coronary arteries without coronary artery vasospasm during 
cardiac catheterization (Bellamy et al., 1998). Therefore, “syndrome X” is a clustering of 
clinical signs and symptoms that indicate myocardial ischemia on exertion in the absence of 
evident coronary artery disease. 
Most available evidence points to CMVD as the pathology responsible for “syndrome X”. 
Zeiher et al (1995) found a suboptimal increase in coronary blood flow (CBF) in response to 
the endothelium-dependent vasodilator acetylcholine compared with an optimal increase in 
CBF in response to the endothelium-independent vasodilator papaverine, in patients with 
“syndrome X” (Zeiher, Krause, Schachinger, Minners, & Moser, 1995). In addition, a 
subsequent study of patients with “syndrome X” showed similar suboptimal CBF response 
to both endothelium-dependent and endothelium-independent vasodilators (Chauhan, 
Mullins, Taylor, Petch, & Schofield, 1997).  
The central nervous system (CNS) has also been implicated in the process of microvascular 
angina, “syndrome X”, and CMVD in general. Major CNS events such as massive strokes 
and subarachnoid hemorrhages sometimes lead to chest pain and diffuse ST- wave 
abnormalities on ECG thought to be induced in part by alterations in the autonomic 
adrenergic innervation of the coronary arteries (Kono et al., 1994). In one extreme but rare 
disease entity called “Stress-Related Cardiomyopathy” or Takotsubo (Japanese for “octopus 
trap”) Disease, a single event of extreme physical or emotional stress by itself can induce 
cardiac ischemia characterized by ST- segment abnormalities on electrocardiogram (ECG) 
and segmental wall akinesis (typically the apical wall) on ECHO giving way to the “octopus 
trap” appearance of the heart muscle (Bybee & Prasad, 2008; Kume et al., 2005; Tsuchihashi 
et al., 2001). In addition, several cases of toxic pheochromocytoma have been observed to 
cause cardiac ischemia and ST- wave abnormalities (Shaw, Rafferty, & Tait, 1987; Yamanaka 
et al., 1994). Researchers have generally applied the terms “neurogenically-stunned 
myocardium” or “catecholamine myopathy” to these anectodal cases.  
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6. Measurement of coronary microvascular function 
Investigators have been using a variety of direct and indirect methods to measure blood 
flow through the small coronary arterioles in order to facilitate the study of the coronary 
microcirculation. One direct method for measurement is the passage of a guide wire tipped 
with a thermistor probe and pressure sensor into the epicardial arteries to measure blood 
flow by thermodilution (Vesely & Dilsizian). Indirect methods of measurement have 
included transthoracic echocardiography with doppler flow analysis (TTE-DR), contrast 
stress echocardiography, thallium scintigraphy, positron emission tomography using 
82rubidium as a marker, and cardiovascular magnetic resonance (CMR) using gadolinium as 
a flow tracer. Many of these tests are expensive, time-consuming, expose patients to 
radioactivity, and provide limited information on the microvasculature. Still, the ultimate 
goal of each modality is to measure coronary perfusion based on several mathematic 
equations. Coronary blood flow (CBF) is the measurement of the amount of blood that 
passes through a cross section of the artery per unit of time. Coronary flow reserve (CFR) is 
a calculation of the ratio of maximally-stimulated CBF within a particular coronary artery to 
the CBF through the same artery at rest. Flow is maximized using physical or chemical 
stimuli to cause vasodilation. A ratio of less than 2 – 2.5 is considered abnormal (G. A. Lanza 
& Crea, 2010). Regional myocardial blood flow (MBF), which equals the amount of blood 
flow (milliliters/minute/gram) through a segment of myocardium, can also be measured 
(Vesely & Dilsizian). A normal resting MBF is usually 0.6 – 1.3 ml/min/g and should 
increase 3 – 4 fold during the peak response (Vesely & Dilsizian). In thallium scintigraphy, 
the injection of a vasodilator simulates an increase in cardiac stress by preferentially dilating 
normal vessels that in turn potentially divert blood flow from diseased vessels. A post-stress 
disparity in blood flow will appear in the form of an abnormal redistribution of thallium, 
the radioactive marker. Large vessel occlusions typically appear as segmental areas of 
decreased blood flow corresponding to the perfusion territories of one or more of the main 
epicardial coronary arteries with or without associated cardiac wall motion abnormalities. 
By comparison, microvascular disease often appears as patchy isolated areas of decreased 
blood flow, most often with no evidence of associated wall motion abnormalities (G. A. 
Lanza & Crea, 2010). All of these imaging modalities carry a certain margin of error, and, 
while they can be instrumental in locating a large coronary vessel occlusion, they often do 
not provide helpful information in cases of CMVD (Maseri et al., 2009). 
7. Treatment 
The various etiologies of CMVD as well as the lack of data from clinical trials preclude a 
definitive treatment regimen. As a result, multiple pharmacologic attempts have been made 
to limit CMVD induced morbidity and mortality. CMVD is typically treated similarly to 
coronary artery disease. Beta-blockers, nitrates and calcium channel blockers have long been 
used for CMVD, but only beta-blockers have shown beneficial effects in clinical trials. 
Additional agents such as angiotensin-converting enzyme inhibitors and angiotensin II 
receptor blockers have also been considered for persistent symptoms despite optimal anti-
ischemic drug therapy. Alpha adrenergic antagonists, statins, estrogens, xanthine 
derivatives, adenosine and tricyclic antidepressants have also been investigated for 
treatment of CMVD-induced angina. Other experimental therapies include GLP-1, L-
arginine, nicorandil, tetrahydrobiopterin and nitrite. This section will examine the evidence 
in support of the pharmacologic treatment of CMVD.  
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7.1 Anti-anginals 
Beta blockers, nitrates and calcium channel blockers are the conventional anti-anginal drugs 
used most often for ischemic chest pain with associated ECG changes in the presence or 
absence of coronary artery lesions. There are no definitive trials indicating a superior anti-
anginal therapy for the treatment of CMVD. However, beta blockers seem to be the most 
effective at decreasing the severity and frequency of chest pain and they are considered first 
line therapy. One randomized, double-blinded prospective trial found that beta blockers, 
but not calcium channel blockers or nitrates, significantly reduced chest pain episodes in 
patients diagnosed with cardiac “syndrome X” (Gaetano Antonio Lanza, Colonna, Pasceri, 
& Maseri, 1999). Similarly, in 16 patients with transient myocardial ischemia and normal 
coronary angiography randomized to treatment with propanolol, verapamil or placebo, 
those patients receiving propanolol had significantly fewer episodes of ischemic chest pain 
when compared to placebo (Bugiardini, Borghi, Biagetti, & Puddu, 1989).  
Nitrates are frequently used to treat chest pain but their effectiveness in coronary 
microvascular dysfunction is unclear. Radice et al (1994) showed that exercise duration and 
time to 1-mm ST-segment depression in patients with CMVD improved with nitroglycerin 
administration, albeit significantly less than in patients with CAD (Radice, Giudici, 
Albertini, & Mannarini, 1994). Similarly, another study showed an improvement in time to 
angina and peak ST-segment depression with nitroglycerin administration (Bugiardini et al., 
1993). However, approximately 50% of patients CMVD taking sublingual nitrates for chest 
pain experience minimal relief (J. Kaski et al., 1995) and exercise tolerance tests for patients 
with CMVD worsened with nitrate use (G. Lanza, Manzoli, Bia, Crea, & Maseri, 1994; 
Radice et al., 1996).  
Similarly, calcium channel blockers (CCB) have limited effectiveness in the treatment of 
CMVD. A 4 week treatment with nisoldipine (a dihydropyridine CCB) significantly 
increased exercise duration and time to angina in patients with CMVD (Özçelik, Altun, & 
Özbay, 1999). Similarly, a 4-week trial of nifedipine or verapamil (a non-dihydropyridine 
CCB) showed a significant improvement in exercise tolerance and angina (Cannon, Watson, 
Rosing, & Epstein, 1985). Montorsi et al (1990) showed improvement in ST-segment 
depression during exercise in patients with CMVD treated with nifedipine for 4 weeks 
(Montorsi et al., 1990). In contrast, Lanza et al (1999) demonstrated that calcium channel 
blockers did not decrease the number of episodes of chest pain (Gaetano Antonio Lanza et 
al., 1999). In addition, a 7-day treatment with verapamil made no difference in the frequency 
of episodes of ST-segment depression, measured by continuous ECG monitoring over 2 
days (Bugiardini et al., 1989).  
7.2 Statins 
The role of statins in the primary and secondary prevention of cardiovascular events has 
been well established, as has the improvement of endothelial function via non-cholesterol 
lowering effects (Rosenson & Tangney, 1998). Statins are beneficial in patients with CMVD 
and they are commonly used in patients with hypercholesterolemia. In a randomized, 
placebo-controlled study, pravastatin improved exercise duration and time to ST-segment 
depression in patients with CMVD (Kayikcioglu et al., 2003). Similar results were reported 
by Fabian et al (2004) using simvastatin (Fábián et al., 2004). Pizzi et al (2004) found that a 6-
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month trial of atorvastatin and ramipril significantly improved exercise tolerance and 
symptoms of chest pain secondary to CMVD, possibly through the reduction of oxidative 
stress (Pizzi, Manfrini, Fontana, & Bugiardini, 2004).  
7.3 Angiotensin converting enzyme inhibition 
As mentioned above, angiotensin converting enzyme inhibitors (ACE-I) have been 
associated with improvement of chest pain and ECG-findings in patients with CMVD (Pizzi 
et al., 2004). Kaski et al (1994) found an increase in exercise time and time to ST-segment 
depression in patients with reduced coronary flow taking enalapril (Juan Carlos Kaski, 
Rosano, Krzyzowska-Dickinson, Martuscelli, & Romeo, 1994). Evidence from Nalbantgil et 
al (1998) further supported these findings in patients with CMVD taking cilazapril 
(Nalbantgil et al., 1998). Long-term inhibition of ACE is associated with improved nitric 
oxide bioavailability (Chen, Hsu, Wu, Lin, & Chang, 2002), which may be one mechanism by 
which ACE-Is reduce episodes of chest pain in patients with CMVD.  
7.4 Metformin 
Metformin has been shown to have vasculoprotective properties and can improve 
endothelial function (Mather, Verma, & Anderson, 2001). These vascular effects have proven 
to be beneficial for patients with CMVD. In a randomized, double blinded, placebo 
controlled study, Jadhav et al (2006) found that metformin improved vascular function and 
decreased myocardial ischemia in non-diabetic women with chest pain and 
angiographically normal coronary arteries (Jadhav et al., 2006). This study found a 
significant reduction in the incidence of chest pain and ST-segment depression during 
exercise treadmill testing. Similarly, Kapinya et al (2008) conducted a retrospective, 
observational study investigating cardiac stress test results in patients with chest pain 
without cardiac biomarker rise. These investigators found that patients previously taking 
metformin had significantly less ischemia and infarction compared to patients previously 
taking insulin or insulin secretagogues (Kapinya, Nijjar, Stanek, & Amanullah, 2008).  
7.5 Hormone replacement therapy/estrogen 
The high proportion of peri- and post-menopausal women with CMVD raises questions 
about the lack of estrogen as a pathophysiologic cause of CMVD and its replacement as a 
potential therapy. Hormone replacement therapy has been shown to improve endothelial 
function (J C Kaski, 2006; Roque et al., 1998; Sitges et al., 2001) as well as decrease episodes 
of angina (Rosano et al., 1996) and increase exercise tolerance (Albertsson, Emanuelsson, & 
Milsom, 1996). However, the risk of breast cancer and thromboemoblic disease has limited 
the possibilities of hormone replacement therapy for CMVD (Committee, 2004; 
Investigators, 2002).  
7.6 Other pharmacologic therapies 
7.6.1 Imipramine 
Imipramine, a tricyclic antidepressant, has been shown to improve chest pain symptoms but 
not quality of life in patients with CMVD (Cox, Hann, & Kaski, 1998). The hypothesized 
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mechanism of this effect is not through vasoactive pathways, but through its visceral 
analgesic effects (Cannon et al., 1994). The American College of Cardiology recommends 
imipramine for treatment of CMVD in patients who have failed treatment with risk factor 
reduction, beta blockers, calcium channel blockers or nitrates (Wright et al., 2011).  
7.6.2 L-arginine 
L-arginine is a substrate for the production of NO by NOS (Palmer, Ashton, & Moncada, 
1988). In patients with angina and normal coronary arteries, intravenous infusion of L-
arginine restored nitric oxide activity and resulted in the improvement of endothelial 
function (Piatti et al., 2003). In addition, chronic L-arginine supplementation enhanced NO 
synthesis in diabetic animals (Kohli et al., 2004), and improved coronary microvascular 
endothelial function in humans (Lerman, Burnett, Higano, McKinley, & Holmes, 1998). 
These findings demonstrate a potential role for L-arginine in the treatment of CMVD.  
7.6.3 Tetrahydrobiopterin 
Tetrahydrobiopterin (BH4) is a co-factor required for the production of NO from L-arginine 
and molecular oxygen (Scott-Burden, 1995), and BH4 deficiency causes decreased NO 
production by diabetic coronary endothelium (Meininger et al., 2000). In addition, 
intracoronary BH4 improved acetylcholine-induced microvascular dilator responses in 
patients with endothelial dysfunction in vivo. Thus, supplementation with BH4 may be a 
novel therapeutic means to increase NO availability for patients with coronary 
microvascular disease (Setoguchi, Mohri, Shimokawa, & Takeshita, 2001). 
7.6.4 Alpha antagonists 
Alpha adrenergic antagonists decrease alpha-mediated vasoconstriction and have been 
hypothesized to improve CMVD symptoms. However, a study by Bøtker et al (1998) proved 
disappointing. Doxazosin did not increase exercise tolerance or time to ST-segment 
depression during exercise versus placebo (Bøtker, Sonne, Schmitz, & Nielsen, 1998).  
7.6.5 Xanthine derivatives 
Xanthine derivatives such as theophylline, bamiphylline and aminophylline have been used 
to reduce chest pain symptoms related to CMVD. Emdin et al (1989) found that 
aminophylline had a beneficial effect on exercise induced chest pain and ischemic ECG 
changes in patients with CMVD (Emdin, Picano, Lattanzi, & L'Abbate, 1989). The proposed 
mechanism for this is through the inhibition of pain transmission through adenosine 
receptor blockade. In addition, myocardial flow maldistribution (elicited by inconsistent 
adenosine release in the presence of increased coronary arteriolar resistance) may also have 
been prevented, but this was not measured directly (Emdin et al., 1989). 
7.6.6 Nicorandil 
Nicorandil (nicotinamide nitrate) is a hybrid between a nitrate and an activator of ATP-
sensitive potassium channels. Its vasodilatory mechanisms include guanylyl cyclase 
activation and hyperpolarization (Akai et al., 1995) which preferentially relaxes VSMC in the 
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microcirculation (Akai et al., 1995). Ito et al demonstrated preservation of microvascular 
integrity by intravenous nicorandil after coronary ischemia and reperfusion (Ito et al., 1999). 
Ikeda et al (1994) found that post-angiography treatment with nicorandil improved 
coronary microvascular function and was associated with earlier recovery of ST segment 
elevation and greater regional wall motion in the infarcted area after reperfusion (Ikeda et 
al., 2004). In addition, in a prospective study, patients with end-stage renal disease who 
were taking oral nicorandil prior to an ischemic coronary event had improved outcomes 
after revascularization (Ishii et al., 2007). 
7.6.7 Nitrite 
Until recently, nitrite was typically thought of as a biologically inactive metabolite of nitric 
oxide metabolism. However, more recent findings have determined that the generation of 
NO from the reduction of nitrite can occur in vivo, under a variety of physiologic and 
pathophysiologic conditions (Vitturi & Patel, 2011). Nitrite is cardioprotective after episodes 
of ischemia and reperfusion in a variety of experimental models, and clinical trials are 
underway to determine the vasculoprotective and cardioprotective actions of nitrite therapy 
in patients with cardiovascular disease (Calvert & Lefer, 2009). 
7.6.8 Glucagon-like peptide-1 (GLP-1) 
GLP-1 is an incretin hormone that regulates post-prandial metabolism and blood glucose 
concentration. GLP-1 is also biologically active in the cardiovascular system. GLP-1 
improves endothelial function in vivo (Basu et al., 2007; T. Nystrom, 2008; Thomas Nystrom 
et al., 2004), attenuates the expression of pro-inflammatory cytokines (Liu, Hu, Simpson, & 
Dear, 2008) and adhesion molecules (Liu, Dear, Knudsen, & Simpson, 2009) in cultured 
endothelial cells, decreases inflammatory injury in intact endothelium (Dozier et al., 2009), 
and protects myocardium from ischemia/reperfusion injury in isolated heart models and in 
vivo (Ban et al., 2008; Bose, Mocanu, Carr, Brand, & Yellon, 2004, 2005; Bose, Mocanu, Carr, 
& Yellon, 2007; B. B. Dokken, Labonte, Davis-Gorman, & McDonagh, 2007; Huisamen, 
Genade, & Lochner, 2008; Sonne, Engstrom, & Treiman, 2008; Timmers et al., 2009). The 
mechanisms of GLP-1 in the vasculature are not well-understood, but preliminary findings 
suggest that it may decrease endothelial production of ROS (Bloomgarden; Brownlee, 2006) 
and enhance endothelium-dependent vasodilation through nitric oxide (NO) signaling (Ban 
et al., 2008; Basu et al., 2007; Tesauro et al., 2009). We recently reported that GLP-1 prevents 
coronary microcirculatory dysfunction in swine when administered after cardiac arrest and 
resuscitation (Betsy B Dokken et al., 2009). Endogenous GLP-1 is decreased in patients with 
type 2 diabetes, who incidentally are more likely to have CMVD. GLP-1-receptor agonists 
are currently FDA approved for the treatment of hyperglycemia in patients with type 2 
diabetes. Substantial effort is currently underway to determine the mechanisms of the 
protective effects of GLP-1 and its related peptides.  
In summary, the optimal therapy for CMVD is far from defined. In a recent study 
investigating the long-term prognoses of patient’s with CMVD, Lamendola et al (2010) 
found that chest pain episodes remained unchanged in one-third of patients and worsened 
significantly in 14% despite treatment with either beta-blockers, calcium channel blockers, 
nitrates, ACE inhibitors or statins (Lamendola et al., 2010). 
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8. Conclusion 
The coronary microcirculation modulates blood flow throughout the heart, and thus is of 
major importance in both health and disease. The presence of CMVD complicates the 
presentation and management of patients with CAD. Due to the multifactorial nature of 
CMVD and to the difficulty associated with accurately measuring its function, the coronary 
microcirculation has received limited attention. In order to determine appropriate strategies 
for the diagnosis and management of CMVD, the physiology, pathophysiology and 
pharmacology of the coronary microcirculation demands further investigation. 
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